Assessment of diagnostic performance of organs at risk with fluorodeoxyglucose (FDG) – positron emission tomography (PET) [18F-FDG PET/CT] in some selected cancers / (Record no. 175975)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05502namaa22004571i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GICUC |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20251211125211.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 251118b2024 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 612.1122 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 612.1122 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.12.04.Ph.D.2025.No.A |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Nourhan Mohamed Elsoudy Fakhry Abdelrahman, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Assessment of diagnostic performance of organs at risk with fluorodeoxyglucose (FDG) – positron emission tomography (PET) [18F-FDG PET/CT] in some selected cancers / |
| Statement of responsibility, etc. | by Nourhan Mohamed Elsoudy Fakhry Abdelrahman ; Supervised Prof. Dr. Maha Anwar Ali, Dr. Hanan Hussien Amer Dr. Lamiaa Mahmoud Abdelazeez, Dr. Hossam Mahmoud Yassin. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | تقييم الأداء التشخيصي للأعضاء المعرضة للخطر عند إجراء التصوير المقطعي البوزيتروني بإستخدام مادة الفلوروديوكسي جلوكوز المعنونة على الفلورين 18 في بعض الأورام السرطانية |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2025. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 65 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 53-61. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | Whole-body fluorodeoxyglucose F18 (18F-FDG) is the most common radiopharmaceutical use in PET/CT imaging for cancer staging. Although radiopharmaceutical for PET/CT examination has been acknowledged for its safety and efficacy, the internal dosimetry and effective dose (ED) from the examinations are rarely discussed. Hence, this study aimed to evaluate radiation ED and influencing factors of 18F-FDG PET/CT in breast cancer and lymphoma patients. The findings contribute to refining imaging protocols, optimizing radiation exposure, and enhancing the clinical utility of PET/CT in cancer diagnostics and monitoring. Significant correlations were observed between PET effective dose and physiological factors such as age, weight, blood glucose level (BLG), and injected dose, particularly in NHL patients, with a strong negative correlation between PET effective dose and tumor-to-liver ratio (TLR). Based on our results, we recommend excluding patients with blood glucose levels below 80 mg/dL from PET/CT protocols. Additionally, to minimize CT effective doses and adhere to the ALARA principle, reducing tube-current modulation is advised, as it significantly impacts DLP values and the overall effective dose in PET/CT procedures. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | يُعد الفلوروديوكسي جلوكوز المشع F18 (18F-FDG) أكثر الأدوية المشعة شيوعًا في تصوير PET/CT لتحديد مراحل السرطان. وعلى الرغم من الاعتراف بسلامة وكفاءة الأدوية المشعة المستخدمة في فحوصات PET/CT، إلا أن الجرعات الداخلية والجرعة الفعالة (ED) الناتجة عن هذه الفحوصات نادرًا ما يتم مناقشتها. لذلك، هدفت هذه الدراسة إلى تقييم الجرعة الفعالة للإشعاع والعوامل المؤثرة على فحص F-FDG PET/CT18 لدى مرضى سرطان الثدي والليمفوما. تُسهم النتائج في تحسين بروتوكولات التصوير، وتقليل التعرض للإشعاع، وتعزيز الفائدة السريرية لتقنية PET/CT في تشخيص السرطان ومراقبته.<br/>تمت ملاحظة ارتباطات كبيرة بين الجرعة الفعالة لـ PET والعوامل الفسيولوجية مثل العمر، الوزن، مستوى الجلوكوز في الدم (BLG)، والجرعة المحقونة، خاصةً لدى مرضى الليمفوما غير الهودجكينية (NHL)، مع وجود ارتباط سلبي قوي بين الجرعة الفعالة لـ PET ونسبة الورم إلى الكبد (TLR). بناءً على نتائجنا، نوصي باستبعاد المرضى الذين تكون مستويات الجلوكوز في الدم لديهم أقل من 80 مجم/ديسيلتر من بروتوكولات PET/CT. بالإضافة إلى ذلك، ولتقليل الجرعات الفعالة للأشعة المقطعية والالتزام بمبدأ ALARA، يُنصح بتقليل تعديل تيار الأنبوب نظرًا لتأثيره الكبير على قيم منتج طول الجرعة (DLP) والجرعة الفعالة الإجمالية في إجراءات PET/CT. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biophysics |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | الفيزياء الحيوية |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | 18F-FDG |
| -- | PET/CT |
| -- | Effective dose |
| -- | SUV Lymphoma |
| -- | Breast cancer |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Maha Anwar Ali |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hanan Hussien Amer |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lamiaa Mahmoud Abdelazeez |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hossam Mahmoud Yassin |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2025 |
| Supervisory body | Maha Anwar Ali |
| -- | Hanan Hussien Amer |
| -- | Lamiaa Mahmoud Abdelazeez |
| -- | Hossam Mahmoud Yassin |
| Universities | Cairo University |
| Faculties | Faculty of Science |
| Department | Department of Medical Biophysics |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 18.11.2025 | 92517 | Cai01.12.04.Ph.D.2025.No.A | 01010110092517000 | 18.11.2025 | 18.11.2025 | Thesis |